HUGEL announced on the 6th that its consolidated operating profit for the second quarter of this year was 56.7 billion won, an increase of 33.6% compared to the same period last year. Revenue for the same period reached 110.3 billion won, up 15.5% year-on-year, marking the highest quarterly performance ever.
For the first half of this year, HUGEL's revenue surpassed 200 billion won, with operating profit exceeding 95 billion won. The company cited the overseas sales of botulinum toxin and hyaluronic acid (HA) fillers, which account for 63% of total revenue, increasing by 21% year-on-year to 69.8 billion won as a reason for its performance growth.
In particular, HUGEL is the first and only domestic corporation to obtain approvals in the three major toxin markets of the United States, China, and Europe, contributing to strong regional revenue, with exports accounting for 73% of total toxin and filler sales in the second quarter.
By item, the botulinum toxin "Botulax (export name: Retibot)" recorded sales of 61.2 billion won, a 20% increase year-on-year, and cumulative sales for the first half exceeded 100 billion won.
Since its launch in the U.S. in March of this year, additional shipments to the U.S. have been made in June, and stable growth has been added in Asia-Pacific countries such as China, Taiwan, and Australia. Sales of HA fillers ("The Chaeum", "Vylin Skin Booster HA") reached 34.1 billion won, benefiting from solid growth in the Asia-Pacific and European markets. Revenue from the cosmetics sector ("Wellajuu", "Vylin BR") explosively increased by approximately 105% year-on-year to 13.6 billion won.
A HUGEL official said, "In addition to our major product lines of botulinum toxin and HA fillers, we achieved record quarterly sales and operating profit, and successfully surpassed 200 billion won in revenue for the first half of the year with our new growth sector in cosmetics."
He added, "In the second half, we plan to continue focusing on increasing our export penetration rate in the U.S. based on the excellence and competitiveness of HUGEL's toxin formulations, while strengthening our leading position in China and expanding our market share in emerging markets such as the Middle East."